Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019-Reference-Cited by-同舟云学术

Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019

Published:2020-09-28 Issue:7 Volume:73 Page:e1762-e1765
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Martinot Martin¹^ORCID,Jary Aude²,Fafi-Kremer Samira³⁴,Leducq Valentin²,Delagreverie Heloise³⁴^ORCID,Garnier Marc⁵,Pacanowski Jérôme⁶,Mékinian Arsène⁷^ORCID,Pirenne France⁸⁹,Tiberghien Pierre⁸¹⁰,Calvez Vincent²,Humbrecht Catherine¹¹,Marcelin Anne-Geneviève²,Lacombe Karine¹²

Affiliation:

1. Infectious Diseases Department, Hôpitaux Civils de Colmar, Colmar, France

2. Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Pitié-Salpêtrière Hospital, Department of Virology, Paris, France

3. Virology Laboratory, Strasbourg University Hospital, Strasbourg, France

4. Strasbourg University, INSERM, IRM UMR-S 1109, F-67000 Strasbourg, France

5. Sorbonne Université, GRC 29, APHP, DMU DREAM, Anesthesiology and Intensive Care Department, Saint-Antoine Hospital, Paris, France

6. Infectious Diseases Department, Saint-Antoine Hospital, APHP – Sorbonne Université, Paris, France

7. Sorbonne Université, Internal Medicine Department, Inflammation-Immunopathology-Biotherapy Department (DMU i3D), Saint-Antoine Hospital, AP-HP, Paris, France

8. Etablissement Français du Sang, La Plaine St-Denis - France

9. Institut Mondor de Recherche Biomédicale, Unité 955, Equipe 2: Transfusion et Maladies du Globule Rouge, INSERM, EFS, Université Paris-Est Créteil, Créteil, France

10. UMR 1098 RIGHT Inserm Université de Franche-Comté Etablissement Français du Sang, Besançon

11. Etablissement Français du sang Grand Est, Strasbourg, France

12. Sorbonne Université, Inserm IPLESP, Infectious Diseases Department, Saint-Antoine Hospital, APHP, Paris, France

Abstract

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly discovered virus for which remdesivir is the only antiviral available. We report the occurrence of a mutation in RdRP (D484Y) following treatment with remdesivir in a 76-year-old female with post-rituximab B-cell immunodeficiency and persistent SARS-CoV-2 viremia. A cure was achieved after supplementation with convalescent plasma.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa1474/39306065/ciaa1474.pdf

Reference12 articles.

1. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature;Tepasse;Br J Haematol,2020

2. Remdesivir for the treatment of Covid-19;Beigel;N Engl J Med,2020

3. Remdesivir for 5 or 10 days in patients with severe Covid-19;Goldman;N Engl J Med,2020

4. Overwhelming mutations or SNPs of SARS-CoV-2: a point of caution;Vankadari;Gene,2020

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA;Antiviral Research;2024-10

2. Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and management;Clinical Microbiology and Infection;2024-08

3. The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19;Seminars in Hematology;2024-08

4. SARS-CoV-2 Resistance to Small Molecule Inhibitors;Current Clinical Microbiology Reports;2024-06-24

5. Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review;Transplant Infectious Disease;2024-05-29